Regencell Bioscience (RGC) Financials: Revenue & Earnings
RGC$7.03-0.24 -3.30%
$3.49B
Market Cap
-286.44
P/E
—
Forward P/E
51
Score
Regencell Bioscience (RGC) Financials: Revenue & Earnings
RGC price $7.03 -0.24 -3.30%
- Ticker
- RGC
- Price
- $7.03
- Change
- -0.24 -3.30%
- Market cap ?
- $3.49B
- P/E ?
- -286.44
- Dividend yield ?
- 0.00%
- Beta ?
- 1.43
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stocklytics score
- 51
- Value
- 52
- Quality
- 52
- Growth
- 50
Stocklytics score rationale: value 52, quality 52, growth 50.
Financials
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Regencell Bioscience Holdings Limited is a biotechnology firm specializing in Traditional Chinese Medicine (TCM). Its core activities revolve around the research, development, and market introduction of TCM solutions specifically designed to address neurocognitive disorders and related degeneration. The company places a particular emphasis on conditions such as attention deficit hyperactivity disorder (ADHD) and…
Earnings and financials
Regencell Bioscience Holdings Limited (RGC) trades at $7.03, with a market cap of $3.49B and a trailing P/E of -286.44. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.
Financials
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Insights · Dividends · Forecast · Financials · Learn